Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional Dose Meningococcal Polysaccharide Vaccine in Africa
NCT00271479Phase 4Completed
- Sponsor
- Illumina
- Start
- Jun 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of quadrivalent meningococcal polysaccharide vaccine in meningococcal meningitis (2 arms), sponsored by Illumina. Primary endpoints: Immunogenicity of 1/5 dose of meningococcal polysaccharide vaccine and Immunogenicity of 1/10 dose of meningococcal polysaccharide vaccine. Started Jun 2004; status: completed.
02
Drugs
quadrivalent meningococcal polysaccharide vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT00271479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271479.